|Bid||0.9100 x 900|
|Ask||0.9500 x 800|
|Day's Range||0.9076 - 0.9799|
|52 Week Range||0.6500 - 4.2500|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
Subscribe to Yahoo Finance Plus to view Fair Value for FRLN
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued progress in FLT190 in Fabry disease and FLT201 in Gaucher disease, with new country and site initiations paving the way for delivery of key milestones in both programs Leadership team further strengthened by appointing new Chief People Officer LONDON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutic